Vir Biotechnology, Inc.

Equities

VIR

US92764N1028

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 28/06/2024 am IST			5-day change	1st Jan Change
8.87 ^USD	-2.53%		-0.89%	-11.83%

26/06	Vir Biotechnology Says FDA Cleared IND Application for Chronic Hepatitis D Drug Combination	MT
26/06	Vir Biotechnology's Tobevibart, Elebsiran Combo Gets FDA Fast Track Status for Chronic Hepatitis Delta	DJ

Vir Biotechnology, Inc. Elects Elliott Sigal as Director

May 24, 2023 at 01:36 am IST

Vir Biotechnology, Inc. at the Annual Meeting of Stockholders on May 19, 2023, elected Elliott Sigal as Class I Director, to serve until the Company's 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.

Latest news about Vir Biotechnology, Inc.

Vir Biotechnology Says FDA Cleared IND Application for Chronic Hepatitis D Drug Combination	26/06	MT
Vir Biotechnology's Tobevibart, Elebsiran Combo Gets FDA Fast Track Status for Chronic Hepatitis Delta	26/06	DJ
Vir Biotechnology, Inc. Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection	26/06	CI
Transcript : Vir Biotechnology, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 02:00 PM	12/06
Morgan Stanley Adjusts Price Target on Vir Biotechnology to $15 From $12, Maintains Equal-Weight Rating	06/06	MT
Sector Update: Health Care Stocks Steady Premarket Wednesday	05/06	MT
Sector Update: Health Care	05/06	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell as Focus Shifts to Market Reports This Week	05/06	MT
Vir Biotechnology Says Mid-Stage Trial for Tobevibart, Elebsiran Show Clinically Significant Efficacy	05/06	MT
Transcript : Vir Biotechnology, Inc. - Special Call	05/06
Vir Biotechnology, Inc. Announces New Preliminary Data from its Phase 2 SOLSTICE Hepatitis Delta Clinical Trial Evaluating tobevibart, an Investigational Monoclonalantibody, and Elebsiran	05/06	CI
Vir Biotechnology, Inc. Appoints Mark D. Eisner as Executive Vice President and Chief Medical Officer, Effective June 3, 2024	29/05	CI
Transcript : Vir Biotechnology, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 04:20 PM	15/05
Transcript : Vir Biotechnology, Inc., Q1 2024 Earnings Call, May 02, 2024	03/05
Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q1 Revenue $56.4M, vs. Street Est of $11.7M	03/05	MT
Vir Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05	CI
Cytokinetics Appoints Sung Lee as CFO	27/04	MT
Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Chief Financial Officer, Effective May 3, 2024	18/04	CI
Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Executive Vice President, effective May 3, 2024	18/04	CI
Transcript : Vir Biotechnology, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 07:30 AM	13/03
Vir Biotechnology Completes Enrollment in Phase 2 Chronic Hepatitis Delta Trial Ahead of Schedule	05/03	MT
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule	05/03	CI
Vir Biotechnology's Q4 Loss Widens, Revenue Declines	23/02	MT
Vir Biotechnology, GSK Terminate Collaboration on Flu	23/02	DJ
Transcript : Vir Biotechnology, Inc., Q4 2023 Earnings Call, Feb 22, 2024	23/02

Chart Vir Biotechnology, Inc.

Duration

Period

More charts

Company Profile

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Vir Biotechnology, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

8.87 USD

Average target price

30.75 USD

Spread / Average Target

+246.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VIR BIOTECHNOLOGY, INC.	-11.83%	1.24B
MODERNA, INC.	+21.85%	46.93B
LONZA GROUP AG	+37.63%	39.08B
IQVIA HOLDINGS INC.	-8.05%	38.48B
ALNYLAM PHARMACEUTICALS, INC.	+29.04%	31.01B
CELLTRION, INC.	-13.75%	26.14B
ICON PUBLIC LIMITED COMPANY	+10.65%	25.88B
MEDPACE HOLDINGS, INC.	+38.43%	12.53B
BIO-TECHNE CORPORATION	-6.92%	11.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.29%	10.65B

Other Biotechnology & Medical Research